Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events: From Mechanism to Patient Care.

Manouchehri A, Kanu E, Mauro MJ, Aday AW, Lindner JR, Moslehi J
Arterioscler Thromb Vasc Biol. 2020 40 (2): 301-308

PMID: 31875699 · PMCID: PMC6993877 · DOI:10.1161/ATVBAHA.119.313353

Targeted oncology therapies have revolutionized cancer treatment over the last decade and have resulted in improved prognosis for many patients. This advance has emanated from elucidation of pathways responsible for tumorigenesis followed by targeting of these pathways by specific molecules. Cardiovascular care has become an increasingly critical aspect of patient care in part because patients live longer, but also due to potential associated toxicities from these therapies. Because of the targeted nature of cancer therapies, cardiac and vascular side effects may additionally provide insights into the basic biology of vascular disease. We herein provide the example of tyrosine kinase inhibitors utilized in chronic myelogenous leukemia to illustrate this medical transformation. We describe the vascular considerations for the clinical care of chronic myelogenous leukemia patients as well as the emerging literature on mechanisms of toxicities of the individual tyrosine kinase inhibitors. We additionally postulate that basic insights into toxicities of novel cancer therapies may serve as a new platform for investigation in vascular biology and a new translational research opportunity in vascular medicine.

MeSH Terms (6)

Cardiovascular Diseases Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive Patient Care Protein-Tyrosine Kinases Protein Kinase Inhibitors

Connections (1)

This publication is referenced by other Labnodes entities: